A retrospective review of glargine use in pregnancy.
To review the obstetric outcome of 240 diabetic pregnancies maintained on basal glargine insulin. This is a retrospective review of the medical data from 240 pregnant diabetics who received glargine as a basal insulin. Perinatal outcome was abstracted from August 29, 2001, to December 31, 2007. Mean maternal age was 33 years (SD +/- 5). Seventy-seven percent (184 of 240) of the women were diagnosed with gestational diabetes. The remaining 23% (56 of 240) had a diagnosis of type 2 diabetes. Weekly evaluation of each woman's daily 7x/d fingersticks yielded an individual mean capillary glucose value. These individual mean capillary glucose values were used to calculate a mean value for our sample population. This overall mean capillary glucose value for the 240 parturients was 112 +/- 14.8 mg/dL. The mean neonatal birth weight was 3,142 +/- 606 g. Only 4 neonates had birth weights > 4,000 g (4,365, 4,384, 4,535 and 4,624). None of the neonates were hypoglycemic. Prenatal glargine appears to be well tolerated with acceptable perinatal outcome. For well-controlled pregestational diabetics, consideration should be given to continuing glargine during pregnancy.